NASDAQ: CASI | 中文 | Contact Us

Press Release

CASI Pharmaceuticals Reports First Quarter 2017 Financial Results

ROCKVILLE, Md., May 15, 2017 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported financial results for the three months ended March 31, 2017.

CASI reported a net loss for the first quarter of 2017 of ($1.7 million), or ($0.03) per share, compared with a net loss of ($1.8 million), or ($0.04) per share, for the same period last year. The smaller net loss stems from a decrease in non-cash compensation expense associated with the timing of stock option issuances, offset by an increase in costs related to the expansion of our China operations.

As of March 31, 2017, CASI had cash and cash equivalents of $25.5 million.

Dr. Ken Ren, Chief Executive Officer, commented, “Our first quarter financial results were as expected and reflect the operational efficiencies we continue to achieve. We continue to make progress with our programs, while also pursuing business development opportunities to expand our pipeline, and remain committed to becoming a fully-integrated multi-national pharmaceutical company.”

About CASI Pharmaceuticals, Inc.

CASI is a U.S. based, late-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a focus on commercialization in China. CASI’s product pipeline features (1) our lead proprietary drug candidate, ENMD-2076, in multiple Phase 2 clinical trials, (2) MARQIBO®, ZEVALIN® and EVOMELA®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory process for market approval in China, and (3) proprietary early-stage candidates in preclinical development. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is available at and in CASI’s filings with the U.S. Securities and Exchange Commission.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, the difficulty of executing our business strategy in China; our inability to predict when or if our product candidates will be approved for marketing by the China Food and Drug Administration authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at

(Financial Table Attached)
2017 2016
Total revenues $ - $ -
Research and development $ 1,049,286 $ 1,018,757
General and administrative $ 644,164 $ 765,075
Net loss $(1,700,182) $ (1,794,366)
Net loss per share attributable to common shareholders (basic and diluted) $ (0.03) $ (0.04)
Weighted average number of shares outstanding (basic and diluted) 60,196,574 40,207,041
Cash and cash equivalents $ 25,528,952 $ 13,944,509

CASI Pharmaceuticals, Inc.
Rui Zhang
Solebury Trout
Xuan Yang

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More